One certified definition per KPI, used identically by dashboards, the Performance Brief, the Sandbox and the CRM feed.
31 certified KPIs
| KPI | Family | Definition | Business rule | Numerator / Denominator | Source | Refresh | Owner | Audience | Ver. | Changed |
|---|---|---|---|---|---|---|---|---|---|---|
Total active commercial patients K01 | Persistence | All active commercial patients: active new starts plus distinct EAP/trial patients transitioned to commercial product; inactive patients excluded. | Total active commercial patients = active new starts + transitioned EAP/trial patients. | Active new starts + active transitioned patients / — | SD 867, Hub | Daily | Brand Analytics | ExecBrand | v1.3 | W14 |
New starts (weekly) K02 | Demand | Patients receiving their first commercial dose in the reporting week. | First dose date within Mon–Sun of Launch Week; EAP transitions excluded. | First commercial doses in week / — | Hub | Weekly | Brand Analytics | ExecBrandField | v1.1 | W3 |
Referral → first dose (median days) K03 | Journey | Median days from referral received at treating site to first commercial dose. | Median over patients dosed in trailing 4 weeks. | Median of day differences / Patients dosed trailing 4 wks | Hub, SD 867 | Weekly | Patient Services | ExecBrand | v1.0 | Pre-launch |
Coverage approval rate K04 | Access | Share of adjudicated PA requests approved (initial or on appeal). | Approved ÷ (Approved + Denied final); pending excluded. | Approved PAs / Final adjudicated PAs | Hub | Weekly | Market Access | ExecPayer | v1.1 | W6 |
EAP/trial transition % K06 | Transition | Share of eligible EAP/OLE patients who received a commercial dose. | 18 transitioned ÷ 22 eligible. | Transitioned patients / Eligible EAP/OLE patients | EAP registry, Hub | Weekly | Medical Ops | ExecBrand | v1.3 | W14 |
Median time to coverage K07 | Access | Median days from hub enrollment to coverage approval. | Patients approved in trailing 4 weeks. | Median days / Approvals trailing 4 wks | Hub | Weekly | Market Access | ExecPayer | v1.0 | Pre-launch |
Confirmed FUS+ patients (cumulative) K08 | Demand | Unique newly confirmed pathogenic / likely pathogenic FUS+ patients. | Distinct tokenized patients with a P/LP FUS result. | Positive FUS results / — | Lab / genetic testing | Weekly | Medical Ops | ExecBrand | v1.0 | Pre-launch |
Referral rate K09 | Journey | Share of confirmed diagnoses referred to a treating site. | Referred ÷ diagnosed, cumulative. | Referred patients / Confirmed diagnoses | Lab, Hub | Weekly | Patient Services | BrandField | v1.0 | Pre-launch |
Hub enrollment conversion K10 | Journey | Share of referred patients enrolled in hub. | Enrolled ÷ referred. | Hub enrolled / Referred | Hub | Weekly | Patient Services | Brand | v1.0 | Pre-launch |
Benefits verification TAT K11 | Access | Median days hub enrollment → BV complete. | Median, trailing 4 wks. | Median days / BV completed | Hub | Weekly | Patient Services | Payer | v1.0 | Pre-launch |
Coverage → first dose (median days) K12 | Journey | Median days from coverage approval to first dose. | Median, trailing 4 wks. | Median days / Patients dosed | Hub, SD 867 | Weekly | Patient Services | BrandField | v1.0 | Pre-launch |
Stalled patients K13 | Journey | Patients whose days in current stage exceed the stage threshold. | days_in_stage > threshold(stage). | Stalled patients / Active pipeline | Hub | Weekly | Patient Services | BrandField | v1.1 | W7 |
Sites activated K14 | Distribution | Sites with contracting, SD account and IT procedure capability confirmed. | Site status = Activated or later. | Activated sites / — | CRM, SD | Weekly | Trade | ExecField | v1.0 | Pre-launch |
Sites with first order K15 | Distribution | Activated sites with ≥1 SD order. | Distinct ship-to with order count ≥ 1. | Sites ordered / Sites activated | SD 867 | Daily | Trade | BrandField | v1.0 | Pre-launch |
Site reorder rate K16 | Distribution | Sites with ≥2 SD orders. | Distinct ship-to with order count ≥ 2. | Reordering sites / Sites with first order | SD 867 | Daily | Trade | BrandField | v1.0 | Pre-launch |
SD units shipped K17 | Distribution | Vials shipped from SD to treating sites. | Sum of 867 ship quantity, net of returns. | Units / — | SD 867 | Daily | Trade | Brand | v1.0 | Pre-launch |
Denial rate by reason K18 | Access | Distribution of PA denials by coded reason. | Hub denial reason codes, mapped to 6 families. | Denials by reason / All denials | Hub | Weekly | Market Access | Payer | v1.0 | Pre-launch |
Appeal overturn rate K19 | Access | Share of resolved appeals overturned. | Overturned ÷ resolved appeals. | Overturned / Resolved appeals | Hub | Weekly | Market Access | Payer | v1.0 | Pre-launch |
Account pipeline (suppressed) K20 | Field | Active pipeline patients per account, small-cell suppressed. | Counts 1–4 displayed as <5 in field-facing outputs. | Pipeline patients at account / — | Hub | Weekly | Commercial Ops | Field | v1.1 | W4 |
New commercial starts K21 | Persistence | Cumulative first commercial doses, excluding EAP/trial transitions. | Distinct new-start tokens ever receiving a commercial dose; transition tokens excluded. | New commercial starts / — | Hub dispense events | Weekly | Brand Analytics | ExecBrand | v1.3 | W14 |
Active new-start patients K22 | Persistence | New commercial starts still active on treatment; EAP/trial transitions excluded. | New commercial starts minus discontinued patients or patients past their expected dose date. | Active new-start patients / — | Hub + SD 867 | Weekly | Brand Analytics | ExecBrand | v1.3 | W14 |
EAP/trial transitioned K23 | Transition | Distinct EAP/trial patients transitioned to commercial product and active; additional to active new starts. | Count registry tokens with transitioned status and active commercial dosing. | EAP/trial transitioned / — | EAP registry + Hub | Weekly | Brand Analytics | ExecBrand | v1.3 | W14 |
Priority-account pathway adoption K24 | Journey | % of priority accounts showing verified recognition, FUS testing and referral behavior. | Account counts only when all three behaviors are verified in the trailing 26 weeks. | Priority accounts with verified recognition, FUS testing and referral behavior / Priority accounts (30) | CRM, EHR, claims | Weekly | Commercial Ops | ExecBrandField | v1.0 | W14 |
Treatment-decision completion (30 days) K25 | Journey | % of evaluated qualifying patients with a documented disposition within 30 days of evaluation. | Denominator: evaluated qualifying patients at least 30 days past evaluation. | Evaluated qualifying patients with a documented disposition within 30 days / Evaluated qualifying patients ≥30 days past evaluation | Hub, EHR | Weekly | Patient Services | ExecBrand | v1.0 | W14 |
New qualifying FUS+ patients K26 | Demand | Unique newly confirmed pathogenic / likely pathogenic FUS+ patients. | Distinct tokenized patients with a P/LP FUS result. | Newly confirmed P/LP FUS+ patients / — | Genetic testing (partner TBC), EHR | Weekly | Medical Ops | ExecBrand | v1.0 | W14 |
Treatment-center readiness K27 | Distribution | % of selected centers meeting all clinical, operational, access and support requirements. | Center counts only when all four checklist parts are met. | Selected centers meeting all 4 readiness requirements / Selected treatment centers (26) | Center readiness checklist, SD 867 | Weekly | Trade | ExecBrandField | v1.0 | W14 |
Final denial rate K28 | Access | % of final coverage decisions that are denials after appeals. | Final denials ÷ final adjudicated decisions; pending excluded. | Final coverage denials after appeals / Final adjudicated coverage decisions | Hub, claims | Weekly | Market Access | ExecPayer | v1.0 | W14 |
Avg days submission → approval K29 | Access | Average days from a complete PA submission to coverage approval. | Approvals in trailing 4 weeks; incomplete submissions start the clock when completed. | Sum of days complete submission → approval / Approvals in trailing 4 weeks | Hub | Weekly | Market Access | ExecPayer | v1.0 | W14 |
Median days decision → first dose K30 | Journey | Median days from documented treatment decision to first commercial dose. | Patients dosed in trailing 4 weeks. | Median of days treatment decision → first dose / Patients dosed in trailing 4 weeks | Hub, SD 867 | Weekly | Patient Services | ExecBrand | v1.0 | W14 |
Month-6 persistence K31 | Persistence | % of initiated commercial patients still on treatment at month 6 after first dose. | Not yet evaluable at Launch Week 14: no cohort has reached month 6. Interim measure shown separately: still active since first dose (31 started, 29 active), which is not month-6 persistence. | Initiated patients still on treatment at month 6 / Initiated patients whose first dose was at least 6 months ago | SD 867, claims, Hub | Monthly | Brand Analytics | ExecBrand | v2.0 | W14 |
Sales attainment (% of forecast) K32 | Demand | Net sales versus forecast expressed only as % attainment, national and by region. | Cumulative net sales ÷ cumulative forecast to date; shown as a percentage, never as currency. | Cumulative net sales to date / Cumulative forecast to date (shown only as % attainment) | SD 867, Hub, internal sales | Weekly | Brand Analytics | ExecBrand | v1.0 | W14 |
Governance · Read-only view